Targeting Wnt/β-Catenin Pathway by Flavonoids: Implication for Cancer Therapeutics

Nutrients. 2023 Apr 26;15(9):2088. doi: 10.3390/nu15092088.

Abstract

The Wnt pathway has been recognized for its crucial role in human development and homeostasis, but its dysregulation has also been linked to several disorders, including cancer. Wnt signaling is crucial for the development and metastasis of several kinds of cancer. Moreover, members of the Wnt pathway have been proven to be effective biomarkers and promising cancer therapeutic targets. Abnormal stimulation of the Wnt signaling pathway has been linked to the initiation and advancement of cancer in both clinical research and in vitro investigations. A reduction in cancer incidence rate and an improvement in survival may result from targeting the Wnt/β-catenin pathway. As a result, blocking this pathway has been the focus of cancer research, and several candidates that can be targeted are currently being developed. Flavonoids derived from plants exhibit growth inhibitory, apoptotic, anti-angiogenic, and anti-migratory effects against various malignancies. Moreover, flavonoids influence different signaling pathways, including Wnt, to exert their anticancer effects. In this review, we comprehensively evaluate the influence of flavonoids on cancer development and metastasis by focusing on the Wnt/β-catenin signaling pathway, and we provide evidence of their impact on a number of molecular targets. Overall, this review will enhance our understanding of these natural products as Wnt pathway modulators.

Keywords: Wnt/β-catenin signaling; anticancer; flavonoids; natural product.

Publication types

  • Review

MeSH terms

  • Flavonoids / pharmacology
  • Flavonoids / therapeutic use
  • Humans
  • Immunotherapy
  • Neoplasms* / drug therapy
  • Wnt Signaling Pathway*
  • beta Catenin

Substances

  • Flavonoids
  • beta Catenin

Grants and funding

This research was supported by a grant provided by the Scientific Research Deanship at the University of Ha’il, Saudi Arabia (project number (MDR-22037)).